NCT04726215

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Status unknown Phase 2 Last updated 29 September 2023

What this trial tests

Phase 2 trial testing [18F]F AraG in Non Small Cell Lung Cancer in 50 participants. Status unknown.

Timeline

15 April 2021

Primary endpoint
15 October 2024

15 October 2024

Quick facts

Lead sponsor	CellSight Technologies, Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	15 April 2021
Primary completion	15 October 2024
Estimated completion	15 October 2024
Sites	3 locations across United States

Drugs / interventions tested

• [18F]F AraG — full drug profile →

Conditions studied

• Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

CellSight Technologies, Inc. — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox.
   Li C, Han C, Duan S, Li P, et al · · 2022 · cited 23× · PMID 34887338 · DOI 10.2967/jnumed.121.261976
2. Molecular Immune Targeted Imaging of Tumor Microenvironment.
   Rakhshandehroo T, Smith BR, Glockner HJ, Rashidian M, et al · · 2022 · cited 19× · PMID 35223381 · DOI 10.7150/ntno.66556
3. Imaging of Activated T Cells.
   Sako MO, Larimer BM. · · 2023 · cited 12× · PMID 36460341 · DOI 10.2967/jnumed.122.264097
4. Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.
   Abenavoli EM, Linguanti F, Calabretta R, Delgado Bolton RC, et al · · 2023 · cited 11× · PMID 38067379 · DOI 10.3390/cancers15235675
5. [<sup>18</sup>F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
   Levi J, Das M, Vasanawala MS, Behl D, et al · · 2024 · cited 8× · PMID 39448270 · DOI 10.2967/jnumed.124.268253
6. Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.
   Martin S, Wendlinger L, Zitti B, Hicham M, et al · · 2024 · cited 3× · PMID 39196448 · DOI 10.1186/s13550-024-01142-1
7. Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.
   Lauwerys L, Smits E, Van den Wyngaert T, Elvas F. · · 2022 · cited 3× · PMID 35625811 · DOI 10.3390/biomedicines10051074
8. Illuminating immunotherapy response via precision T cell-targeted PET imaging.
   Glazer SE, Kummar S, Mittra E. · · 2024 · cited 2× · PMID 39104861 · DOI 10.3389/fmed.2024.1233913